In the long dark tunnel that has been 2020, November stands out as the month that light appeared. Some might see it as a bright light, others as a faint light - but it is unmistakably a light.
On
A couple of days later, the
The latest COVID-19 vaccine announcement comes from
In case that sounds disappointing, bear in mind that these are interim results and the figures might change. Also, the Oxford vaccine was given to one group of volunteers as two standard doses, which showed 62% effectiveness, and another group of volunteers as a smaller dose followed by a standard second dose. This raised effectiveness to 90%.
It's not immediately clear why this is the case. Professor
There were no cases of severe COVID-19 in those who received the vaccine. And it seems to generate a protective immune response in older people. Although we'll have to wait for the final breakdown of results to get clarification on that.
Effectiveness is not the only measure
Despite the Oxford vaccine having lower overall effectiveness than the
Another crucial factor is storage. The Oxford vaccine can be stored in a domestic fridge. The need for sustained freezing across the whole vaccine journey from factory to clinic at ultra-low temperatures - as seen with the
The Oxford vaccine, based on a viral vector, is also cheaper (around
Equitable distribution
As I have previously discussed, equitable distribution of new vaccines is vital, especially for low- and middle-income countries who don't have the profile or purchasing power of wealthier countries. GAVI - a global health partnership that aims to increase access to immunisation in poor countries - has worked for years to address this very point. It set up the COVAX initiative in 2020, which has access to 700 million doses of COVID vaccine if clinical trials are successful.
Oxford and
An excellent start
These commitments will clearly not be enough for immediate global coverage, but it is an excellent start. Around 9% of the world's population live in extreme poverty, and the health systems around them are fragile. With promises for equitable vaccine distribution, there is hope that the poorer populations around the world will not be forgotten. The global health community must keep its focus on this area.
What does this announcement mean for the world? Potentially a huge amount. But remember that the trials are not yet complete and, at the time of writing, the regulators have yet to approve any of the new vaccine candidates. Even when those hurdles are cleared, we still need to vaccinate the world, which requires successfully navigating the complex obstacles of distance, terrain, politics, cold-chain logistics and human behaviour.
The global pandemic is not over and won't be for a long time yet - but the light is getting brighter.
Copyright The Conversation Africa. Distributed by AllAfrica Global Media (allAfrica.com)., source